Bio Techne Corp Stock Current Valuation
| TE1 Stock | 71.50 0.50 0.69% |
Valuation analysis of Bio Techne Corp helps investors to measure Bio-Techne Corp's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Bio-Techne Corp's price fluctuation is very steady at this time. Calculation of the real value of Bio Techne Corp is based on 3 months time horizon. Increasing Bio-Techne Corp's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Bio-Techne Corp's intrinsic value may or may not be the same as its current market price of 71.50, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 71.5 | Real 69.88 | Hype 72.0 | Naive 71.72 |
The intrinsic value of Bio-Techne Corp's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bio-Techne Corp's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bio Techne Corp helps investors to forecast how Bio-Techne stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio-Techne Corp more accurately as focusing exclusively on Bio-Techne Corp's fundamentals will not take into account other important factors: Bio Techne Corp Company Current Valuation Analysis
Bio-Techne Corp's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bio-Techne Corp Current Valuation | 13.06 B |
Most of Bio-Techne Corp's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bio Techne Corp has a Current Valuation of 13.06 B. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all Germany stocks is notably lower than that of the firm.
Bio-Techne Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio-Techne Corp's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio-Techne Corp could also be used in its relative valuation, which is a method of valuing Bio-Techne Corp by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in current valuation category among its peers.
Bio-Techne Fundamentals
| Current Valuation | 13.06 B | |||
| Price To Book | 7.56 X | |||
| Price To Sales | 12.34 X | |||
| Revenue | 1.11 B | |||
| EBITDA | 413.76 M | |||
| Net Income | 272.05 M | |||
| Total Debt | 243.41 M | |||
| Cash Flow From Operations | 325.27 M | |||
| Price To Earnings To Growth | 1.11 X | |||
| Market Capitalization | 16.22 B | |||
| Total Asset | 2.29 B | |||
| Z Score | 39.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 2.29 B |
About Bio-Techne Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio-Techne Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bio-Techne Stock Analysis
When running Bio-Techne Corp's price analysis, check to measure Bio-Techne Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio-Techne Corp is operating at the current time. Most of Bio-Techne Corp's value examination focuses on studying past and present price action to predict the probability of Bio-Techne Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio-Techne Corp's price. Additionally, you may evaluate how the addition of Bio-Techne Corp to your portfolios can decrease your overall portfolio volatility.